Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD).
暂无分享,去创建一个
[1] Edward R Zartler,et al. Fragonomics: the -omics with real impact. , 2014, ACS medicinal chemistry letters.
[2] Paul G Wyatt,et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.
[3] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[4] P. Hirth,et al. Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.
[5] Simon J F Macdonald,et al. Factors determining the selection of organic reactions by medicinal chemists and the use of these reactions in arrays (small focused libraries). , 2010, Angewandte Chemie.
[6] Didier Rognan,et al. Fragment-based approaches and computer-aided drug discovery. , 2012, Topics in current chemistry.
[7] T. Ritter,et al. Late-stage fluorination: fancy novelty or useful tool? , 2015, Angewandte Chemie.
[8] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[9] Stefan Wetzel,et al. Natural-product-derived fragments for fragment-based ligand discovery , 2012, Nature Chemistry.
[10] Nicolas Guimond,et al. Rhodium(III)-catalyzed heterocycle synthesis using an internal oxidant: improved reactivity and mechanistic studies. , 2011, Journal of the American Chemical Society.
[11] A. Stamford,et al. Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. , 2013, Current opinion in chemical biology.
[12] A. Nadin,et al. Leitstruktur‐orientierte Synthese: eine Alternative für die Synthesechemie , 2012 .
[13] Harren Jhoti,et al. The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.
[14] Christopher W Murray,et al. Efficient exploration of chemical space by fragment-based screening. , 2014, Progress in biophysics and molecular biology.
[15] Marcel L Verdonk,et al. Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.
[16] Allan M Jordan,et al. The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. , 2011, Journal of medicinal chemistry.
[17] Ajay,et al. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.
[18] Niklas Blomberg,et al. Design of compound libraries for fragment screening , 2009, J. Comput. Aided Mol. Des..
[19] Frank Glorius,et al. Rh(III)-catalyzed directed C-H olefination using an oxidizing directing group: mild, efficient, and versatile. , 2011, Journal of the American Chemical Society.
[20] Nathan Brown,et al. Fragment-based hit identification: thinking in 3D. , 2013, Drug discovery today.
[21] T. Hwang,et al. Rh(III)-catalyzed C-H activation and double directing group strategy for the regioselective synthesis of naphthyridinones. , 2013, Journal of the American Chemical Society.
[22] Thomas R. Ward,et al. Biotinylated Rh(III) Complexes in Engineered Streptavidin for Accelerated Asymmetric C–H Activation , 2012, Science.
[23] A. Hopkins,et al. The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.
[24] A. M. Giannetti,et al. De novo fragment design: a medicinal chemistry approach to fragment-based lead generation. , 2013, Journal of medicinal chemistry.
[25] M. Gaunt,et al. A concise and scalable strategy for the total synthesis of dictyodendrin B based on sequential C-H functionalization. , 2015, Angewandte Chemie.
[26] Daniel A Erlanson,et al. Introduction to fragment-based drug discovery. , 2012, Topics in current chemistry.
[27] G. Klebe. Applying thermodynamic profiling in lead finding and optimization , 2015, Nature Reviews Drug Discovery.
[28] C. Murray,et al. The rise of fragment-based drug discovery. , 2009, Nature chemistry.
[29] Irini Akritopoulou-Zanze,et al. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. , 2009, Drug discovery today.
[30] Edgar Jacoby,et al. Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.
[31] Daniel A Erlanson,et al. Learning from our mistakes: the 'unknown knowns' in fragment screening. , 2013, Bioorganic & medicinal chemistry letters.
[32] Gianni Chessari,et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. , 2007, Journal of medicinal chemistry.
[33] S. F. Macdonald,et al. Faktoren für die Auswahl organischer Reaktionen in der medizinischen Chemie und die Anwendung dieser Reaktionen in Arrays (kleinen fokussierten Bibliotheken) , 2010 .
[34] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[35] Warren R. J. D. Galloway,et al. Drug discovery: A question of library design , 2011, Nature.
[36] Andrew J. Woodhead,et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function , 2012, Nature chemical biology.
[37] T. Magee. Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening. , 2015, Bioorganic & medicinal chemistry letters.
[38] N. Cramer,et al. Chiral Cyclopentadienyl Ligands as Stereocontrolling Element in Asymmetric C–H Functionalization , 2012, Science.
[39] P. Clemons,et al. Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.
[40] G. Chessari,et al. Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. , 2015, Journal of medicinal chemistry.
[41] Brian Dymock,et al. Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets , 2004, J. Chem. Inf. Model..
[42] Roderick E Hubbard,et al. Experiences in fragment-based lead discovery. , 2011, Methods in enzymology.
[43] Tobias Ritter,et al. Fluorierung in späten Synthesestadien: extravagante Neuheit oder nützliches Hilfsmittel? , 2015 .
[44] Monya Baker,et al. Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.
[45] T. Rovis,et al. Ligand design for Rh(iii)-catalyzed C–H activation: an unsymmetrical cyclopentadienyl group enables a regioselective synthesis of dihydroisoquinolones , 2014, Chemical Science.
[46] James E. J. Mills,et al. Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics , 2011, J. Comput. Aided Mol. Des..
[47] Channa K. Hattotuwagama,et al. Lead-oriented synthesis: a new opportunity for synthetic chemistry. , 2012, Angewandte Chemie.
[48] Gianni Chessari,et al. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. , 2010, Journal of medicinal chemistry.